Breaking News

U.S. May Home Prices Rise 0.4% From Previous Month: FHFA

Echo Therapeutics to Participate in the Leerink Swann 2014 Global Healthcare Conference

 Echo Therapeutics to Participate in the Leerink Swann 2014 Global Healthcare                                   Conference  PR Newswire  PHILADELPHIA, Feb. 6, 2014  PHILADELPHIA, Feb. 6, 2014 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony^® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Echo's Executive Chairman and Interim CEO, will participate in the Leerink Swann 2014 Global Healthcare Conference in New York, New York.  Mr. Doman will make a corporate presentation to prospective corporate partners and investors at 2:40 PM EST on Thursday, February 13^th.  At the time of the presentation, a live webcast of Mr. Doman's presentation will be available in the Events section of the Company's website at Echo recommends registering at least 15 minutes prior to the scheduled start time to ensure timely access. A replay will be available approximately one hour following the presentation and accessible on for 30 days following the event.  About Echo Therapeutics  Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting.Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting.Echo is also developing its needle-free skin preparation component of Symphony, the Prelude^® SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.  Cautionary Statement Regarding Forward Looking Statements  The statements in this press release that are not historical facts, including the statement about the corporate presentation, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.  For More Information: Christine H. Olimpio Director, Investor Relations and Corporate Communications (215) 717-4104  Connect With Us: - Visit our website at - Follow us on Twitter at - Join us on Facebook at  SOURCE Echo Therapeutics, Inc.  Website: